Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 01, 2024, titled "Zydus Lifesciences receives approval for the name Usnoflast as recommended name for ZYIL1 from the WHO International Non-proprietary Names (INN) .
Press Release Apr 01 2024
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Usnoflast is currently under clinical development for several indications, including rare autoinflammatory diseases and neurological conditions. This press release serves to inform investors and the exchange about this significant development in Zydus Lifesciences' research efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 23 2024
- Press Release Mar 16 2024
- Press Release Mar 14 2024
- Press Release Mar 13 2024
- Press Release Feb 26 2024
Later from Zydus Lifesciences
- Press Release Apr 20 2024
- Zydus Lifesciences Limited Press Release Apr 22 2024
- Press Release Apr 23 2024
- Press Release Apr 26 2024
- Press Release May 04 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences